Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Signs Deals with MultiPlan, Three Rivers

NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed agreements with MultiPlan and Three Rivers Provider Network to provide access to the firm's ConfirmMDx for Prostate Cancer test.

The Liege, Belgium-based molecular diagnostics firm said that the two providers combined cover 67 million lives in the US. MultiPlan, which is a healthcare cost management firm, contracts with 900,000 healthcare providers in the US and offers products to approximately 57 million consumers. Three Rivers is a preferred provider organization with more than 6000,000 providers in its network.

ConfirmMDx is an epigenetic-based test that helps clinicians differentiate patients with true negative biopsies from those at risk for occult cancer.

"These two agreements provide access to ConfirmMDx for 25 percent of the insured population within the US, further enabling market adoption of our test nationwide," MDxHealth CEO Jan Groen said in a statement.

Yesterday, MDxHealth announced that Bostwick Laboratories would offer the test through its urology network in the US.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.